Literature DB >> 6133000

The effect of the acetylator phenotype on the metabolism of sulphasalazine in man.

A K Azad Khan, M Nurazzaman, S C Truelove.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6133000      PMCID： PMC1048982          DOI： 10.1136/jmg.20.1.30

Source DB:  PubMed          Journal:  J Med Genet        ISSN： 0022-2593            Impact factor:   6.318


× No keyword cloud information.
  12 in total

1.  ROLE OF THE FAMILY DOCTOR TODAY IN THE CONTEXT OF BRITAIN'S SOCIAL SERVICES.

Authors:  R M TITMUSS
Journal:  Lancet       Date:  1965-01-02       Impact factor: 79.321

2.  An improved and simplified method of detecting the acetylator phenotype.

Authors:  D A Evans
Journal:  J Med Genet       Date:  1969-12       Impact factor: 6.318

3.  Determination of salicylazosulphapyridine in biological materials.

Authors:  M Sandberg; K A Hansson
Journal:  Acta Pharm Suec       Date:  1973-05

4.  Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine.

Authors:  K A Hansson; M Sandberg
Journal:  Acta Pharm Suec       Date:  1973-03

5.  Determination of free and acetylated 5-aminosalicylic acid in serum and urine after administration of salicylazosulphapyridine.

Authors:  K A Hansson
Journal:  Acta Pharm Suec       Date:  1973-05

6.  The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.

Authors:  A K Azadkhan; S C Truelove; J K Aronson
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

7.  Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects.

Authors:  H Schröder; D A Evans
Journal:  Gut       Date:  1972-04       Impact factor: 23.059

8.  A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

Authors:  A S Dissanayake; S C Truelove
Journal:  Gut       Date:  1973-12       Impact factor: 23.059

9.  The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  Gut       Date:  1973-08       Impact factor: 23.059

10.  Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis.

Authors:  A K Azad Khan; S C Truelove
Journal:  Gut       Date:  1980-08       Impact factor: 23.059
View more
  11 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 2.  Pharmacogenetics and ecogenetics.

Authors:  D P Agarwal; H W Goedde
Journal:  Experientia       Date:  1986-10-15

Review 3.  Variables affecting efficacy and toxicity of sulphasalazine in rheumatoid arthritis. A review.

Authors:  T Pullar; H A Capell
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 4.  Survey of the human acetylator polymorphism in spontaneous disorders.

Authors:  D A Evans
Journal:  J Med Genet       Date:  1984-08       Impact factor: 6.318

Review 5.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

6.  Mesalazine pharmacokinetics and NAT2 phenotype.

Authors:  Hendrik Lück; Martina Kinzig; Alexander Jetter; Uwe Fuhr; Fritz Sörgel
Journal:  Eur J Clin Pharmacol       Date:  2008-08-14       Impact factor: 2.953

7.  Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate.

Authors:  T Pullar; J A Hunter; H A Capell
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

8.  Case Study 10: A Case to Investigate Acetyl Transferase Kinetics.

Authors:  Jennifer L Dumouchel; Valerie M Kramlinger
Journal:  Methods Mol Biol       Date:  2021

Review 9.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of slow-acting antirheumatic drugs.

Authors:  S E Tett
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.